Published • loading... • Updated
MTTI Reports Extended Disease Control Data in Neuroendocrine Tumor Study
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
MTTI Reports Extended Disease Control Data in Neuroendocrine Tumor Study
WEST CHESTER, PA — Molecular Targeting Technologies Inc. reported updated clinical data from 81 patients with gastroenteropancreatic neuroendocrine tumors treated with its experimental radiopharmaceutical EBTATE, results that the company says support continued development of the therapy and its broader albumin-binding drug platform. The West Chester-based clinical-stage radiopharmaceutical developer presented the findings at the 2026 Society of …
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
